Company
3 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
AUG 11, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental labeling approval for an existing combination product; regulatory action that does not contain clinical trial data or efficacy evidence.
JUN 3, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental labeling approval for Qtern (dapagliflozin/saxagliptin); indicates label modification without new efficacy or safety trial data reported here.
JUN 3, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for labeling change to dapagliflozin; does not report clinical trial data or efficacy outcomes.